Highlights
(All comparisons are against the prior year period unless otherwise noted)
- Sales of $887 million increased 9% on a reported basis and 5% organically
- Reported diluted EPS of $1.61 increased 28% and adjusted diluted EPS of $2.00 increased 14%
- Record orders of $988 million increased 13% on a reported basis and increased 10% organically
- Returned capital to shareholders via $76 million of share repurchases and $53 million of dividends
- Raising full year 2026 organic growth and adjusted EPS guidance ranges
NORTHBROOK, IL, April 29, 2026 – IDEX Corporation (NYSE: IEX) today announced its financial
results for the three-month period ended March 31, 2026.
“Our first quarter results demonstrate that our strategy is working, with strong execution across the
portfolio and increasing traction in the markets where we are choosing to compete. The application of
8020 continues to sharpen our priorities and reallocate resources toward opportunities with stronger
growth and margin profiles.”
“We delivered a strong first quarter, with results ahead of our expectations led by continued momentum in our growth platforms within our Health & Science Technologies segment,” said Eric D. Ashleman, IDEX Corporation Chief Executive Officer and President.
“Based on this momentum, we are raising our full-year guidance and are encouraged by how our
strategies are translating into higher-quality growth. We remain focused on disciplined execution as we
continue to build long-term value at IDEX.”
Outlook(1)
- Full year organic sales projected to increase 3% to 4% over the prior year, up from previous
guidance of 1% to 2% - Full year adjusted diluted EPS of $8.35 to $8.55, up from previous guidance of $8.15 to $8.35
- Second quarter 2026 organic sales projected to increase 3% to 4% from the prior year period
- Second quarter 2026 adjusted diluted EPS of $2.07 to $2.12
(1) The Company does not reconcile its forward-looking non-GAAP measures to the most directly comparable U.S. GAAP financial measure
because the timing and magnitude of certain items, including future foreign exchange impacts, acquisitions, divestitures, restructuring costs,
impairments, tax impacts, and other special items, cannot be reasonably estimated at this time without unreasonable effort. The unavailable
information could have a significant impact on GAAP results.
